Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

CVR Medical Corp V.CVM.H

Alternate Symbol(s):  CRRVF

CVR Medical Corp. is a medical technology organization. The Company is focused on the development and advancement of technology at work within the healthcare sector. The Company’s Carotid Stenotic Scan (CSS) is a diagnostic tool designed to detect and determine a level of carotid narrowing for the purpose of identifying patients at risk for Ischemic Stroke. The CSS provides a synergistic tool, which complements other stroke screening technology such as Duplex Doppler ultrasound (DUS), magnetic resonance angiography (MRA) and computed tomography angiography (CTA). The CSS is non-invasive and does not require the use of harmful dyes. It offers its product to patients, payers, and healthcare providers.


TSXV:CVM.H - Post by User

Bullboard Posts
Post by ICT1111on Mar 20, 2020 11:56am
217 Views
Post# 30830696

Two different plans.....

Two different plans.....PLAN A; With the original signed Term Sheet, the restructuring group were hoping to ........ 1/ Install their experienced non-conflicted directors on a no pay basis to start with 2/ Re-negotiate the payables of medical and Global down to a level hoped to be below US$1m. 3/ Re-engage with critical suppliers such as Cannon, The Clinics and the Software engineers. 4/ Secure further loan investment (you can't do a placing when you are subject to a CTO) from top 50 Share-holders so as to provide Medical with funds to get trading again and get this device to the FDA ........ this plan had provisional approval by the TSX ........ once approved, Medical would be free to trade again and would have had an unincumbered path to market ...... it was hoped that at this point the shareprice would be C$0.50+ and the street would be encouraged ...... this would be the environment within which a placing could take place at or around C$0.50 minimising dilution.

PLAN B; The new directors apparently want to retain conflicted directors on full pay and asborb Global and all of its debts giving Global a huge tranche of shares in exchange for the IP (which, rumour has it, is not IP at all, it is in fact computer code which is not 'IPable', rather 'copyrightable' and there is doubt that Global have any rights to the software as they did not pay the engineers!!) So even if the new directors could get this past the TSX they would be going to the street with a requirement for circa US$5m of debt and US$1m required just to get this restarted ...... at what price do you suppose this would be raised 5 cents? 10 cents? Massive dilution if workable at all....... and then there is the question of the software and whether the engineers would go back to work for Peter and his fellow men when they weren't paid?

you decide which plan looks most viable
Bullboard Posts